Posted: Tuesday, August 30, 2022
New research findings on the immunomodulatory molecule called B7 homolog 3, or B7-H3, add to evidence that prostate cancer in men of African ancestry may have a distinct tumor biology. The data have potentially important clinical implications for immunotherapy in this population, according to Tamara L. Lotan, MD, of Johns Hopkins University School of Medicine, Baltimore, and colleagues in Cancer. B7-H3 is part of the B7 superfamily, which includes PD-L1, and was already known to be highly expressed in prostate cancer.
Studying the molecular and immune microenvironment correlates of B7-H3 expression could help to guide trial design and interpretation, explained the team. “Immunotherapies—antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells—targeting B7-H3 are currently in clinical trials,” they wrote. And, as far as they knew, their study may be the first “to examine B7-H3 expression in prostate cancer from a racially diverse cohort with genetic ancestry annotations, the first to correlate B7-H3 expression with quantified immune cell densities, and the first to examine the expression of B7-H3 in paired samples before and after intensive hormonal therapy.”
Dr Lotan and co-investigators described four significant findings from their research:
Disclosure: The study authors’ disclosure information can be found at acsjournals.onlinelibrary.wiley.com.